Published online Feb 21, 2015. doi: 10.3748/wjg.v21.i7.2214
Peer-review started: June 26, 2014
First decision: July 9, 2014
Revised: August 15, 2014
Accepted: September 29, 2014
Article in press: September 30, 2014
Published online: February 21, 2015
Processing time: 230 Days and 11.8 Hours
Acute hepatic failure due to hepatitis B virus (HBV) can occur both during primary infection as well as after reactivation of chronic infection. Guidelines recommend considering antiviral therapy in both situations, although evidence supporting this recommendation is weak. Since HBV is not directly cytopathic, the mechanism leading to fulminant hepatitis B is thought to be primarily immune-mediated. Therefore, immunosuppression combined with antiviral therapy might be a preferred therapeutic intervention in acute liver failure in hepatitis B. Here we report our favourable experience in three hepatitis B patients with fulminant hepatic failure who were treated by combining high-dose steroid therapy with standard antiviral treatment, which resulted in a rapid improvement of clinical and liver parameters.
Core tip: In the reported cases we describe our positive experience with combined glucocorticoid and nucleotide analogue therapy in two cases of severe reactivations of chronic hepatitis B virus (HBV) infection and in one case of acute fulminant HBV infection. Rapid improvement of liver parameters and virological response was obtained in all three cases. Thus, the reported data emphasize the need for the further assessment of this therapeutic strategy and for the development of systematic clinical trials.